Resources

The advantages to building a business in the UK's biotech clusters

Chris Molloy on new pension scale-up fund news, member news from Touchlight, the major GSK investment in Cambridge, a valuable collaboration for Relation and BIA's parliamentary engagement

Find out more about a free, independent review of R&D tax claims for BIA members.

Up to $110 million upfront and success-based milestones collaboration will generate large-scale human cellular perturbation datasets to advance understanding of disease biology.

Moa Technology announces a £22.2 million Series C financing round

Pioneer Group has announced the launch of new regional accelerator programmes designed to support early-stage life science and tech companies accelerate their journey to market.

From first-in-class approvals to billion-dollar deals, Q2 2026 signals a new era for antibody innovation

Chris Molloy on the Q2 2026 finance report, investment in Draig Therapeutics, MHRA meeting, centure capital summit and upcoming BIA events

UK biotech financing hit a five-year high in the second quarter of 2026, with total equity financing reaching £2.11 billion, including a record £2.05 billion in venture capital.

The British Business Bank has invested in Draig Therapeutics as part of its $65 million Series B financing round.

The Milner Therapeutics Institute has joined the o2h Discovery Platinum Partner Programme, enabling eligible companies within its bio-incubator and wider affiliate network to access specialist drug discovery support through the o2h Kickstarter Award.

How to unlock the UK's innovative life sciences and biotech potential

Jane Wall discusses investment in Alchemab Therapeutics, Life Sciences Sector Plan: one year on, regulatory and trade links, Women in Biotech and BIA members lounge

Chris Molloy on scale-up policy, improving treatments pipeline, LSSP, GMM regulation, LLSW, MDUK's Pedal Paddle Peak and Dr Sally Ann Forsyth OBE

Key takeaways as another BIA Summer Party 2026 delivers for the life sciences sector

Myricx Bio reached agreement to be acquired by Novartis for up to $1.5 billion.

Brandon Capital announced the successful exit of its portfolio company Myricx Bio.

The UK’s innovative life sciences sector has called on Government to deliver policy continuity, unlock scale-up investment and improve patient access to new medicines.

Innovation Orbit 2026 is FI Group by EPSA’s international guide to grants, R&D tax credits and public incentives for businesses planning R&D, CAPEX, digital transformation or decarbonisation projects.